The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

Annetrude (J G) de Mooij-van Malsen; Eneda Pjetri; Martien J. Kas

doi:10.1016/j.ejphar.2014.07.043

The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

Annetrude (J G) de Mooij-van Malsen, Eneda Pjetri, Martien J. Kas^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

Animal studies play a central role in the identification and testing of novel drugs for CNS disorders. In his longstanding career, Berend Olivier has significantly contributed to CNS drug discovery by applying and supporting novel views and methodologies in the fields of behavioral neuroscience, pharmacology, and (epi-) genetics. Here we review and put forward some of these integrated approaches that have led to a productive collaboration and new insights into the genetic and epigenetic regulation of neurobehavioural traits related to psychiatric disorders. (C) 2014 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	135-139
Number of pages	5
Journal	European Journal of Pharmacology
Volume	753
DOIs	https://doi.org/10.1016/j.ejphar.2014.07.043
Publication status	Published - 15-Apr-2015
Externally published	Yes

Keywords

Behavior
Psychiatry
Drug targets
Endophenotypes
Mouse
Human
MOUSE AVOIDANCE-BEHAVIOR
GENOME-WIDE ASSOCIATION
BIPOLAR DISORDER
EATING-DISORDERS
MOOD DISORDER
SCHIZOPHRENIA
MICE
SUSCEPTIBILITY
CONSORTIUM
SEQUENCE

Access to Document

10.1016/j.ejphar.2014.07.043

Handle.net

Persistent link

Cite this

@article{332a80a994b74d7e8fc06e6ff8947342,

title = "The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains",

abstract = "Animal studies play a central role in the identification and testing of novel drugs for CNS disorders. In his longstanding career, Berend Olivier has significantly contributed to CNS drug discovery by applying and supporting novel views and methodologies in the fields of behavioral neuroscience, pharmacology, and (epi-) genetics. Here we review and put forward some of these integrated approaches that have led to a productive collaboration and new insights into the genetic and epigenetic regulation of neurobehavioural traits related to psychiatric disorders. (C) 2014 Elsevier B.V. All rights reserved.",

keywords = "Behavior, Psychiatry, Drug targets, Endophenotypes, Mouse, Human, MOUSE AVOIDANCE-BEHAVIOR, GENOME-WIDE ASSOCIATION, BIPOLAR DISORDER, EATING-DISORDERS, MOOD DISORDER, SCHIZOPHRENIA, MICE, SUSCEPTIBILITY, CONSORTIUM, SEQUENCE",

author = "{de Mooij-van Malsen}, {Annetrude (J G)} and Eneda Pjetri and Kas, {Martien J.}",

year = "2015",

month = apr,

day = "15",

doi = "10.1016/j.ejphar.2014.07.043",

language = "English",

volume = "753",

pages = "135--139",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "ELSEVIER SCIENCE BV",

}

TY - JOUR

T1 - The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

AU - de Mooij-van Malsen, Annetrude (J G)

AU - Pjetri, Eneda

AU - Kas, Martien J.

PY - 2015/4/15

Y1 - 2015/4/15

N2 - Animal studies play a central role in the identification and testing of novel drugs for CNS disorders. In his longstanding career, Berend Olivier has significantly contributed to CNS drug discovery by applying and supporting novel views and methodologies in the fields of behavioral neuroscience, pharmacology, and (epi-) genetics. Here we review and put forward some of these integrated approaches that have led to a productive collaboration and new insights into the genetic and epigenetic regulation of neurobehavioural traits related to psychiatric disorders. (C) 2014 Elsevier B.V. All rights reserved.

AB - Animal studies play a central role in the identification and testing of novel drugs for CNS disorders. In his longstanding career, Berend Olivier has significantly contributed to CNS drug discovery by applying and supporting novel views and methodologies in the fields of behavioral neuroscience, pharmacology, and (epi-) genetics. Here we review and put forward some of these integrated approaches that have led to a productive collaboration and new insights into the genetic and epigenetic regulation of neurobehavioural traits related to psychiatric disorders. (C) 2014 Elsevier B.V. All rights reserved.

KW - Behavior

KW - Psychiatry

KW - Drug targets

KW - Endophenotypes

KW - Mouse

KW - Human

KW - MOUSE AVOIDANCE-BEHAVIOR

KW - GENOME-WIDE ASSOCIATION

KW - BIPOLAR DISORDER

KW - EATING-DISORDERS

KW - MOOD DISORDER

KW - SCHIZOPHRENIA

KW - MICE

KW - SUSCEPTIBILITY

KW - CONSORTIUM

KW - SEQUENCE

U2 - 10.1016/j.ejphar.2014.07.043

DO - 10.1016/j.ejphar.2014.07.043

M3 - Article

SN - 0014-2999

VL - 753

SP - 135

EP - 139

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

ER -

The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this